Universal Influenza Vaccines 2018

16-18 April 2018, CHUV, University of Lausanne, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Monday 16th April 2018

10.00
Arrival & Registration & Poster Set-Up

10.40-10.45
Welcome & Opening Remarks
Professor John Oxford (Queen Mary College, University of London, London, UK)

SESSION 1:
PLENARY SESSION I

Moderator: John Oxford (Queen Mary College, University of London, London, UK)

10.45-11.15
‘WHO perspective: Public health views on universal vaccines: What do we want them to achieve?’
Martin Friede (World Health Organization, Geneva, Switzerland)

11.15-11.45
‘What will a government be looking for in a universal influenza vaccine?’
Jon Van Tam (Deputy Chief Medical Officer, UK Department of Health, London, UK)

11.45-12.30
‘Progress in clinical development of novel influenza vaccines’
Sarah Gilbert (University of Oxford, Oxford, UK)

12.30-12.45
Questions & Discussion

12.45-14.00
Lunch Break & Posters

SESSION 2:
PLENARY SESSION II

Moderator: Sarah Gilbert (University of Oxford, Oxford, UK)

14.00-14.30
‘100 million deaths and 1 billion influenza illnesses direct us to a vaccine Manhattan 2 project’
John Oxford (Queen Mary College, University of London, London, UK)

14.30-15.00
‘Influenza vaccine uptake stagnation: A global health failure?’
Bram Palache (Independent Consultant, IFPMA, International Federation of Pharmaceutical Manufacturers & Associations, Geneva, Switzerland)

15.00-15.30
‘Universal influenza vaccines: What is missing?’
Rob Lambkin-Williams (hVIVO Ltd, London, UK)

15.30-15.45
Questions & Discussion

15.45-16.00
Tea Break & Posters

SESSION 3:
PLENARY SESSION III

Moderator: Rob Lambkin-Williams (hVIVO Ltd, London, UK)

16.00-16.30
‘Getting closer to the market: M-001 universal flu vaccine starting pivotal Phase 3 Trial’
Tammy Ben Yedidia (BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel)

16.30-17.00
‘Local production of influenza vaccines: Results from the global action plan for influenza vaccines technology transfer and sustainable production projects’
Christopher Chadwick, Erin Grace Sparrow, Shoshanna Goldin and Claudia Nannei (WHO, Geneva, Switzerland)

17.00-17.20
‘Cross-reactive responses to conserved influenza antigens’
Teresa Lambe (University of Oxford. Oxford, UK)

17.20-17.40
‘FLUCOP project (http://www.flucop.eu/), standardisation of assays to evaluate immune responses to influenza vaccines’
Joanna Waldock and Othmar G. Engelhardt (NIBSC, South Mimms, Potters Bar, Hertfordshire, UK)

17.40-17.50
Questions & Discussion

 

UIV 2018 Delegates

Login details will be supplied after you have registered for the event.


UIV 2018 Sponsors

  • APACI
  • hVIVO
  • DNAvaccine.com
  • BiondVax
  • Vismederi
  • FluConsult
  • ISIRV
  • Aldevron
  • Sanofi Pasteur
  • VaxArt
  • NatureGeneTherapy.com

UIV 2018 Downloads

UIV 2018 Leaflet

UIV 2018 Mailing List

Name
E-mail Address
What is 3+2-1?